231997 Reaching Subgroups at Greatest Risk with New Medical Technologies: Learning from the Human Papillomavirus (HPV) Vaccine

Tuesday, November 9, 2010 : 3:30 PM - 3:45 PM

Helen I. Meissner, PhD , Office of Behavioral and Social Sciences Research, National Institutes of Health, Bethesda, MD
Rebecca Anhang Price, PhD , Clinical Monitoring Research Program, Support to: Applied Cancer Screening Research Branch, NCI, SAIC Frederick, Inc., Rockville, MD
This session, “Reaching Subgroups at Greatest Risk with New Medical Technologies: Learning from the Human Papillomavirus (HPV) Vaccine,” will use the HPV vaccine as a case study for examining factors that influence adoption of new medical technologies among underserved groups. We will review current surveillance data on awareness and use of the HPV vaccine across subgroups at greatest risk of cervical cancer, with a special emphasis on racial and ethnic minorities and the uninsured. The session will highlight factors influencing vaccine uptake, including interest, financing and access. HPV vaccine promotion and payment policies will be described. Proposed presentations: 1) Systematic review of HPV vaccine initiation and completion: surveillance data from national and local studies. (15 minutes) 2) HPV vaccination in the Indian Health Service. (15 minutes) 3) Knowledge of HPV: differences across at-risk groups. (15 minutes) 4) Interest in the HPV vaccine and the potential role of financing and health promotion policies: A perspective from California. (15 minutes)

Helen Meissner will moderate the session and lead 30 minutes of discussion following the presentations.

Learning Areas:
Provision of health care to the public
Social and behavioral sciences

Learning Objectives:
1. Describe factors influencing awareness, access and adoption of new medical technologies. 2. Discuss policies that have the potential to prevent or reduce disparities in technology adoption. 3. Assess surveillance data needed for evaluation of disparities in technology uptake.

Keywords: Cancer Prevention, Health Disparities

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified to present because I have managed a research portfolio on the HPV vaccine and continue to oversee behavioral and social sciences research programs in health.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4296.0: Reaching Subgroups at Greatest Risk with New Medical Technologies: Learning from the Human Papillomavirus (HPV) Vaccine